2025-10-04 - Analysis Report
Okay, here's a report analyzing TransMedics Group Inc. (TMDX) based on the provided data.

## TMDX Analysis Report (September 26, 2025)

**Transmedics Group Inc. (TMDX) is a medical technology company focused on developing and delivering innovative organ preservation systems for transplant surgery.**

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 189.80%
*   **VOO Cumulative Return:** 73.75%
*   **Absolute Divergence (Current):** 117.0
*   **Relative Divergence (Current):** 59.5 (Indicates TMDX's outperformance is in the 59.5th percentile of its historical range relative to VOO.)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the analyzed period. The relative divergence suggests this outperformance, while substantial, is not at the extreme upper end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2019-2021  | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%   | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%   | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0%  | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 111.0%  | 85.5% | 48.0%  | 0.3  | 3.9    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows impressive growth in recent periods (2020-2025), but a significant loss in the earlier period (2019-2021).
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:**  Alpha is largely positive, especially in recent periods, meaning TMDX generated returns above what would be expected based on market movements.  The negative alpha in 2019-2021 is concerning.
*   **Beta:** Beta is low, indicating that TMDX's price is not highly correlated with the market.
*   **Cap(B):** Market capitalization has generally increased.

### 2. Recent Stock Price Movement

*   **Current Price:** $115.69
*   **Previous Close:** $116.07
*   **Change:** -$0.33
*   **5-day Moving Average:** $114.31
*   **20-day Moving Average:** $115.43
*   **60-day Moving Average:** $115.73

**Analysis:** The stock price experienced a minor decrease in the last trading session. The 5-day moving average is below the 20-day moving average, which is also below the 60-day moving average. This *could* indicate a potential short-term downward trend or consolidation. However, the differences are slight.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 52.40 (Neutral)
*   **PPO:** -0.06 (Slightly Bearish)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash" (Strong Buy Signal)
*   **Recent (20-day) Relative Divergence Change:** +0.1 (Short-term Increase)
*   **Expected Return (%):** 50.7% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** The MRI suggests that, based on the analyzed risk factors, the stock is suitable for investment.
*   **RSI:** The RSI is near the neutral level, not indicating overbought or oversold conditions.
*   **PPO:** The PPO being slightly negative suggests a slightly bearish trend in price momentum.
*   **Hybrid Signal:** The hybrid signal indicates a "Strong Buy" with no need to hold cash.
*   **Recent Divergence:** The positive change in relative divergence suggests a recent uptick in performance relative to the S&P 500.
*   **Expected Return:** The 50.7% expected return suggests significant long-term potential outperformance against the S&P 500.
*   **Recent Price Decrease:** The price change is minimal.

### 4. Recent News & Significant Events

*   **[2025-09-24]** Zacks: TMDX is a Strong Growth Stock.
*   **[2025-09-23]** Simply Wall St.: TMDX may be Undervalued by Up To 49%.
*   **[2025-09-23]** Simply Wall St.: Organ Transport Partnership at Mercedes-Benz Group.
*   **[2025-09-22]** MT Newswires: TransMedics Teams Up With Mercedes-Benz to Launch Organ Transport Fleet in Italy.
*   **[2025-09-22]** PR Newswire: TransMedics and Mercedes-Benz Announce Strategic Collaboration in Italy.
*   **[2025-09-19]** Insider Monkey: TMDX: A Bull Case Theory.

**Analysis:** The news headlines are overwhelmingly positive. Several articles highlight growth potential and undervaluation. The collaboration with Mercedes-Benz for organ transport in Italy is a significant development, potentially expanding TMDX's market reach and demonstrating innovation.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.82 (~Buy)
*   **Opinions:** 9
*   **Target Price (avg/high/low):** 140.67 / 170.00 / 114.00
*   **Recent Rating Changes:** No Changes

**Analysis:** Analyst consensus is strongly positive, with a "Buy" rating and an average target price significantly above the current price. The lack of recent rating changes suggests analysts remain confident in their assessments.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 예상 EPS |
|------------|------|----------|
| 2025-07-30 | 0.92 | 0.48     |
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |

**Analysis:** TMDX has consistently beaten EPS estimates in recent quarters, indicating strong financial performance and positive earnings surprises. The significant beat in the most recent quarter (2025-07-30) is particularly noteworthy. The only underperformance was in 2024-10-28

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-06-30 | $0.32B   | 10.97%  |
| 2025-03-31 | $0.27B   | 9.64%   |
| 2024-12-31 | $0.23B   | 3.00%   |
| 2024-09-30 | $0.21B   | 2.01%   |
| 2024-06-30 | $0.19B   | 6.42%   |

**Analysis:**

*   **Revenue:** Revenue has shown consistent growth over the past five quarters.
*   **Profit Margin:** Profit margins remain high, indicating strong pricing power and efficient operations.
*   **Equity:** Equity has increased steadily, reflecting improved financial health.
*   **ROE:** The Return on Equity has increased significantly, demonstrating enhanced profitability relative to shareholder equity.

### 7. Overall Assessment

Based on the provided data, TransMedics Group Inc. (TMDX) appears to be a compelling investment opportunity.

*   **Positive Factors:** Strong historical outperformance vs. the S&P 500, positive recent news flow (especially the Mercedes-Benz partnership), consistent earnings beats, growing revenue and high profit margins, increasing equity and ROE, and a "Buy" consensus from analysts with a significant average target price upside. The MRI suggesting it is suitable for investment.
*   **Considerations:** High Maximum Drawdown indicating high volatility, and some prior periods of negative alpha. Recent PPO indicates bearish trend.
*   **Overall:** TMDX presents a compelling case for investment, especially for those seeking growth potential and willing to tolerate higher volatility. The recent Mercedes-Benz partnership and consistent earnings beats further strengthen the bullish outlook. Given the "Strong Buy" hybrid signal and analyst consensus, a "Buy" recommendation appears justified. However, risk management is important due to the stock's volatility.
